RecruitingPhase 1Phase 2NCT05408559

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Prevention of Age-associated Cardiac and Vascular Dysfunction Through Nrf2 Signaling Using the Nutritional Supplement Sulforaphane

Sponsor

Texas Tech University Health Sciences Center

Enrollment

200 participants

Start Date

Jul 1, 2022

Study Type

INTERVENTIONAL

Conditions

Diastolic Dysfunction Systolic Dysfunction Diastolic Heart Failure

Summary

Our local IRB approved clinical studies seeking proof of principle for the hypothesis that SFN can be safely administered to humans at doses sufficient to protect age-associated cardiac dysfunctions. Beneficial effects of SFN-therapy will be assessed by Pre- and post-intervention echocardiography, and exercise endurance at 0 and 24 weeks. Peripheral blood cells from treated and control subjects will be compared for mitochondrial respiratory function, oxidative damage, pro-inflammatory cytokines, and expression of antioxidant \& anti-electrophile genes.

Eligibility

Min Age: 60 YearsMax Age: 80 Years

Inclusion Criteria4

Age \> 60 years
Diagnosis of HFpEF (HF symptoms with a normal EF (\>/=50 %)
Ability to walk more than 500 feet (by self-report)
Willing to avoid taking all over the counter antioxidant phytochemical supplements (vegetable or fruit-containing supplement pills) during the study

Exclusion Criteria6

Inability to provide informed consent
Diagnosis of active cancer
Inability to read and understand the SF-36 in English
Participants using over the counter antioxidant supplements
Participants with pulmonary or other issues which restrict walking capacity
On oxygen therapy

Interventions

DRUGSulforaphane

Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.